Piramal Pharma Limited — PPTs, 28-04-2026: Investor Presentation

Piramal Pharma saw a 3% YoY revenue dip to ₹8,869 Cr in FY26, though Q4 revenues stabilized. CDMO segment revenue declined 10% to ₹4,915 Cr, while Complex Hospital Generics (CHG) grew 3% to ₹2,703 Cr. Consumer Healthcare (PCH) was a bright spot, jumping 17% to ₹1,274 Cr. FY26 EBITDA fell 28% to ₹1,135 Cr (13% margin). The company reported a net loss of ₹326 Cr, significantly impacted by a ₹196 Cr asset impairment. Net Debt remained stable at ₹4,140 Cr.

Key strategies include US$90Mn capex for CDMO's sterile injectables and payload-linkers in the US, alongside expanding high-growth differentiated offerings. CHG strengthened its portfolio by completing the Kenalog® acquisition. PCH is boosting Power Brands and e-commerce growth. Recent highlights: CDMO saw improved order inflows in H2FY26. CHG initiated lower-cost Sevoflurane supplies from India. The company also maintained a strong quality record with 38 successful regulatory inspections.

Management is optimistic, expecting FY27 growth across all segments, with accelerated EBITDA and PAT, driven by better biopharma funding and strategic initiatives.